The Role of Prostanoids in Atopic Dermatitis by Tetsuya Honda & Kenji Kabashima
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
5 
The Role of Prostanoids in Atopic Dermatitis 
Tetsuya Honda and Kenji Kabashima 
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto  
Japan 
1. Introduction 
Atopic dermatitis (AD) is a common pruritic and chronic inflammatory skin disease, with a 
prevalence of up to 3% among adults and up to 25% among children (Bieber; Guttman-
Yassky et al.; Odhiambo et al., 2009). The clinical features of AD are varied, with patients 
generally having dry skin, but wet eczematous lesions in the acute stage and lichenification 
lesions in the chronic stage (Guttman-Yassky et al., 2011). In terms of histology, an increased 
number of lymphocytes, eosinophils, and mast cells in the dermis are detected. A barrier 
defect with decreased cornification and epidermal hyperplasia are also characteristic 
features of AD (Elias and Schmuth, 2009; Guttman-Yassky et al., 2009). 
AD is a multi-factorial disease that arises from complex interaction between genetic and 
environmental factors. As for its pathogenesis, two models have been proposed: the 
outside-in model and the inside-out model (Bieber, 2008). In the outside-in model, the 
decreased skin barrier function caused by genetic defects, such as mutations in filaggrin, 
allows for the penetration of large immunogenic proteins, which subsequently cause T 
helper type 2 (Th2) deviated immune activation (Elias et al., 2008; Elias and Schmuth, 
2009). In the inside-out model, activation of Th2 cells results in reactive epidermal 
hyperplasia (Nograles et al.; Ong and Leung, 2006). It has been proposed that the lack of 
environmental antigens during childhood lead to reduced T helper type 1 (Th1) cell-
mediated immunity and increased activation of Th2 cells (hygiene hypothesis). In recent 
reports, involvements of T helper type 17 (Th17) cells and T helper type 22 (Th22) cells 
have also been proposed (Koga et al., 2008; Nograles et al., 2009). 
As for the treatment of AD, various therapies have been employed, and the use of topical 
steroids plays a major role in therapies (Guttman-Yassky et al.). Although the use of topical 
corticosteroids is the first-line therapy and provides rapid relief of symptoms, prolonged use 
can cause severe side effects such as skin atrophy. Therefore, alternative therapies with 
fewer and less extreme side effects are needed. 
2. Characteristics of prostanoids 
When tissues are exposed to diverse pathophysiological stimuli, arachidonic acid (AA) is 
released from membrane phospholipids and converted to lipid mediators, such as 
prostanoids, leukotrienes (LTs) and hydroxy-eicosatetraenoic acids (HETEs). Prostanoids, 
including prostaglandins (PG) and thromboxane (TX), are formed by the cyclooxygenase 
(COX) pathway, whereas LTs and HETEs are formed by the 5-, 12- and 15-lipoxygenase 
(LO) pathways. COX has two isoforms, COX-1 and COX-2. While COX-1 is constitutively 
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expressed in cells, COX-2 requires specific stimulation by substances such as acetone and 
the phorbol ester TPA (Narumiya et al., 1999; Scholz et al., 1995). This reaction results in the 
formation of an unstable endoperoxide intermediate PGH2, which, in turn, is metabolized to 
PGD2, PGE2, PGF2a, PGI2, and thromboxane TXA2 by specific synthases. 
Prostanoids are released from cells immediately after their formation. Because they are 
chemically and metabolically unstable, they usually function only locally through their 
specific membrane receptors on target cells (Narumiya et al., 1999). Nine types and subtypes 
of membrane prostanoid receptors are conserved in mammals from mouse to human: two 
subtypes of the PGD receptor (DP (DP1) and the chemoattractant receptor homologous-
molecule expressed on Th2 cells, CRTH2 (DP2)), four subtypes of the PGE receptor (EP1, 
EP2, EP3, and EP4), the PGF receptor (FP), the PGI receptor (IP), and the TXA receptor (TP) 
(Figure 1). All are G protein-coupled rhodopsin-type receptors with seven transmembrane 
domains (Figure 1). The main signal transduction mechanisms of these prostanoid receptors 
are through the regulation of intracellular cyclic adenosine monophosphate (cAMP) 
concentration and intracellular free calcium concentration. DP, EP2, EP4 and IP are Gs-
coupled receptors and elevate intracellular cAMP concentration, while EP3 and CRTH2 are 
Gi-coupled receptors and decrease intracellular cAMP. EP1, FP and TP are Gq and other G 
protein-coupled receptors, which increase intracellular calcium concentration (Narumiya et 
al., 1999). However, most prostanoid receptors may bind with more than one G protein-
coupled receptors via their specific signaling pathway. Recently, individual prostanoid 
receptor gene-deficient mice have been used as models to dissect out the respective roles of 
each receptor in combination with the use of compounds that selectively bind to prostanoid 
 
 
Fig. 1. Biosynthetic pathways of prostanoids. The formation of PGD2, PGE2, PGF2a, PGG2, 
PGH2, and PGI2, and TXA2 from arachidonic acid is shown. The first two steps of the 
pathway (i.e., conversion of arachidonic acid to PGG2 and then to PGH2) are catalyzed by 
COX, and the subsequent conversion of PGH2 to each prostanoid is catalyzed by the 
respective synthase as shown. All are G protein-coupled rhodopsin-type receptors. 
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receptors as agonists or antagonists (Narumiya and FitzGerald, 2001). These genetic and 
pharmacological approaches have revealed new roles for prostanoids and their receptors in 
allergic and immune diseases (Honda et al., 2010). 
In this chapter, we will discuss the recent findings regarding the role of prostanoids in skin 
immunity, and discuss the possible involvement of prostanoids in the pathogenesis of AD, 
and also the clinical potential of receptor-selective drugs as a new therapeutic target for AD. 
3. Production of prostanoids in skin 
Human bodies are exposed to external stimuli continuously. The skin plays an important role 
in self-defense during exposure to foreign antigens and consists of a vast array of immune 
cells, such as keratinocytes (KCs), T cells, B cells, mast cells, eosinophils, fibroblasts, and two 
types of cutaneous dendritic cells (DCs) including epidermal Langerhans cells (LCs) and 
dermal DCs (dDCs). In the normal human skin, immunohistochemical examinations have 
revealed that COX-1 is observed throughout the epidermis, whereas COX-2 exists in more 
differentiated suprabasilar KCs and outer root sheath cells of hair follicles (Leong et al., 1996; 
Torii et al., 2002). Among prostanoids, PGE2 is the main COX product in human epidermal 
homogenates (Hammarstrom et al., 1979). PGD2 has been detected in human skin 
(Hammarstrom et al., 1979), and PGD synthase is present predominantly in LCs, dDCs, 
dermal macrophages and mast cells, but not in KCs (Ruzicka and Aubock, 1987; Ujihara et al., 
1988). Among these, mast cells have been found to be one of the major cellular sources of 
PGD2. TX synthase activity has been found in keratinocytes (Andoh et al., 2007) and high 
levels of TXB2, as a metabolite of TXA2, were detected in the cultured supernatant of LCs and 
DCs (Kabashima et al., 2003a). PGI2 was detected in the skin of the murine AD model 
(Sugimoto et al., 2006). PGF2a, was observed in skin exudates of nickel allergy patients (Lerche 
et al., 1989). In biopsy specimens from patients with AD, PGE2 has been determined in 
biologically active amounts in both lesional and perilesional skin (Fogh et al., 1989). In 
contrast, normal levels of eicosanoids were found in the uninvolved skin of these patients. The 
above findings on the synthesis of prostanoids are summarized in Table 1. 
4. Prostanoid receptor expression in skin 
Adult human KCs express mRNA for all subtypes of PGE2 receptors (Konger et al., 1998; 
Tober et al., 2006) and the expression of all PGE2 receptors has been detected in mouse KCs by 
immunohistochemistry (Tober et al., 2007). Mouse LCs and DCs express DP (Angeli et al., 
2001), EP1, 2, 3, 4 (Kabashima et al., 2003b), and IP (Huang et al., 2001), and T cells express EP1, 
2, 3, 4 (Tilley et al., 2001), IP (Takahashi et al., 2002) and TP (Nataraj et al., 2001). PGE2 
suppresses T cell proliferation and differentiation in the thymus, and interleukin (IL)-1 
production by acting at EP2 and EP4 in vitro (Nataraj et al., 2001). Mast cells express EP1, 2, 3, 
4, DP, and IP (Fedyk and Phipps, 1996; Tilley et al., 2001), and PGE2 acts at EP3 to suppress 
their degranulation (Kunikata et al., 2005). Human eosinophils express EP2, EP4, DP, CRTH2 
and TP (Nguyen et al., 2002; Schratl et al., 2007), and PGE2 seems to prolong eosinophil 
survival (Mita et al., 2002; Peacock et al., 1999). PGE2 suppresses TNF-a production and 
enhances IL-6 production from neutrophils stimulated by lipopolysaccharide (LPS) through 
EP2 and EP4 (Nguyen et al., 2002; Yamane et al., 2000). As summarized in Table 1, prostanoids 
and their receptors are produced and expressed by a wide variety of cells in the skin. This 
varied expression pattern of prostanoids maintains the homeostasis of the human body. 
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 PGDS PGES PGFS PGIS TXS DP CRTH2 EP1 EP2 EP3 EP4 FP IP TP 
Keratinocytes m m, h   m   m, h m, h m, h m, h   m,h 
hLangerhans 
cells 
h m, h   m m, h  m m m m    
Dendritic cells h m, h  m m, h    m, h  m, h  m  
T cells       
m, 
h(Th2)
m m m m, h  m m 
B cells        m, h m, h m, h m, h  m  
Macrophages h m, h  m m, h  m m m m m, h    
Eosinophils h h h  h m m,h  m, h  h   h 
Mast cells, 
basophils 
m, h    h m, h m, h m m m m    
Neutrophils  h   h h m  m, h  m    
Blood vessels  h h h    m, h m, h m, h m, h  
m, 
h 
m, h 
PG; prostaglandin, S; synthase, m; mouse, h; human 
Modified from the reference by Tilley et al. 
Table 1. Expression of prostanoid synthases and prostanoid receptors in the skin 
5. Involvement of prostanoids in the pathogenesis of AD: Analysis based on 
animal models of AD 
As mentioned above, there are multiple pathogenetic factors of AD, but the skin barrier 
dysfunction and Th2 mediated immune response are its general characteristic features. 
Mouse ovalbumin (OVA)-induced dermatitis is one of the most frequently used AD models 
(He et al.; Spergel et al., 1998). In a typical mouse OVA-induced AD model, mice are first 
sensitized with an OVA patch using a transparent bio-occlusive dressing on a shaved and 
tape-stripped area of skin for one week. This sensitization to OVA is repeated in two-week 
intervals. After three to four sensitization cycles, the mice show elevated serum IgE and 
significant eosinophil and Th2-deviated lymphocyte infiltration in the skin, which is similar 
to the pathology of AD. In this model, COX-2 deficient mice and the administration of COX-
2 inhibitor both showed enhanced eosinophil infiltration and elevated IL-4 expression in the 
skin lesion with elevated serum IgE and IgG1 (Laouini et al., 2005). These results suggest 
that COX-2-derived prostanoids play regulatory roles in the development of AD, such as Th 
differentiation and inflammatory cell infiltration in the skin. In the following sections, we 
will discuss how prostanoids are involved in Th differentiation, DC function, and 
inflammatory cell infiltration in skin immunity. 
6. Prostanoids as regulatory factors of Th differentiation 
In older in vitro studies, PGE2 has been regarded as a suppressant of Th1 cells, because of its 
suppressive effect on cell proliferation, differentiation and cytokine production from Th1 
cells (Betz and Fox, 1991; Goodwin and Ceuppens, 1983). However, recent reports indicate 
that several PGE2 receptors are involved in the regulation of Th differentiation in skin 
immunity via multiple pathways and different directions (Figure 2).  
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For example, PGE2-EP1 signaling has been reported to facilitate Th1 differentiation in the 
sensitization process through the skin (Nagamachi et al., 2007). PGE2 produced by DCs in 
draining lymph nodes (dLNs) stimulates EP1 receptors on naïve CD4+ and CD8+ T cells and 
promotes Th1 and Tc1 differentiation (Nagamachi et al., 2007). PGI2-IP signaling promotes 
Th1 and Tc1 differentiation through a cAMP dependent mechanism (Nakajima et al., 2010). 
Intriguingly, IP deficient mice showed enhanced Th2 response such as elevated IgE 
concentration in serum in the mouse OVA-induced asthma model (Nagao et al., 2003), 
suggesting that lack of PGI2-IP signaling might result in a Th2 biased immune response 
through the inhibition of Th1 differentiation.  
The regulatory mechanism of prostanoid signaling on Th differentiation is complex, because 
it depends on the context of immune system. For example, PGE2-EP2/EP4 signaling 
regulates Th1 and Th17 differentiation (Yao et al., 2009). In a weaker co-stimulation 
signaling through CD28, PGE2 suppresses the Th1 differentiation via EP2 and EP4 receptors. 
In the case of strong co-stimulation signaling, however, stimulation of EP2 and EP4 
signaling conversely facilitates the Th1 differentiation through a PI3-kinase-dependent 
mechanism (Yao et al., 2009). These results suggest that the action of prostanoid receptor 
signaling can be changed in a context-dependent manner. EP2 and EP4 signaling also 
regulates the Th17 differentiation. Th17 is a recently identified Th subset, and can be 
detected in a number of diseases, including AD (Guttman-Yassky et al., 2011; Koga et al., 
2008). In vitro, Th17 differentiation is induced from naïve T cells in the presence of IL-6 and 
TGF-b. In this condition, PGE2 acts on naïve T cells through EP2/EP4 signaling and 
suppress the Th17 differentiation in a cAMP-dependent manner. However, PGE2-EP2/EP4 
signaling also acts on DCs and increases the IL-23 production from the DCs. Thus, PGE2 
facilitates the expansion of Th17 (Yao et al., 2009). The blockade of EP4 signaling 
consistently ameliorated the disease progression in a CHS model and an EAE model, which 
are mediated by Th1 and Th17 cells, respectively (Yao et al., 2009). These results clearly 
indicate the importance of prostanoid signaling in Th differentiation in vivo. The facilitation 
effect of PGE2 on Th17 is also reported in human T cells (Boniface et al., 2009). 
7. Prostanoids as regulatory factors of DC function 
In the initial step of sensitization in AD, allergens which enter the skin are captured by skin 
DCs and presented to the naïve T cells in the dLNs. Prostanoids can regulate this step by 
affecting the migration ability or antigen presentation ability of the skin DCs (Figure 2). 
PGE2, which is produced by KCs, acts on EP4 on LCs, and stimulates the migration of LCs 
(Kabashima et al., 2003b). Conversely, stimulation of DP on DCs inhibits the migration of 
skin DCs. Topical administration of DP inhibits the migration of DCs to dLNs and 
significantly suppresses the development of the mouse AD model (Angeli et al., 2001; 
Angeli et al., 2004). Prostanoids also regulate DC-T cell interaction in the priming of naïve T 
cells (Kabashima et al., 2003a). Cutaneous DCs produce abundant TXA2, which acts on naïve 
T cells and increases the motility of T cells, which impairs the stable DC-T cell interaction 
(Kabashima et al., 2003a). TP-deficient mice or wild-type mice treated with a TP antagonist 
during the sensitization period show enhanced CHS responses, indicating that TP signaling 
negatively regulates the priming of T cells in vivo. 
Although the role of IgE in AD is still controversial (Guttman-Yassky et al., 2011), high serum 
IgE is one of the hallmarks of AD. Compared to the analysis of T cells and DCs, the reports 
about the role of prostanoids on B cells are relatively scarce. From the in vivo data using COX-2 
deficient mice or IP deficient mice, which show increased IgE production in OVA sensitization 
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(Laouini et al., 2005), it might be possible that some prostanoid signaling regulates the 
antibody production. In vitro, PGE2 drives Ig class switching to IgE by acting at EP2 and EP4 
on B cells under LPS and IL-4 stimulation in vitro (Fedyk and Phipps, 1996). Whether such 
actions occur in vivo remains unknown, and this should be clarified in future studies. 
8. Prostanoids and Treg induction 
T regulatory cells (Treg) make up one of the T cell subsets which has potent suppressive 
functions in various disease models. There are several reports that analyzed Treg number 
and function in AD patients, but those results are not necessarily consistent (Brandt et al., 
2009; Ou et al., 2004; Schnopp et al., 2007; Verhagen et al., 2006). However, considering the 
fact that loss of Treg in skin can lead to AD-like skin lesions in both human (Ochs et al., 
2005) and mouse (Brunkow et al., 2001), it is very likely that Treg play important roles in the 
pathogenesis of AD. 
It has been well known that ultraviolet (UV) radiation causes immunosuppression, and it is 
one of the effective treatment options for AD. Although multiple suppression mechanisms 
have been proposed, induction of Treg is considered one of the central factors for the 
suppression mechanism. As blocking of prostanoid production by treatment with non-
steroidal anti-inflammatory drugs (NSAIDs) treatment can abolish the immunosuppressive 
effect through UV (Chung et al., 1986; Hart et al., 2002; Walterscheid et al., 2002), it has been 
suspected that prostanoids play important roles in the UV-induced immunosuppression, 
especially in Treg induction. By UV radiation, various prostanoids are produced in the skin, 
with PGE2 being the most abundant prostanoids (Kuwamoto et al., 2000; Ruzicka et al., 1983; 
Soontrapa et al., 2011). Recently, it has been revealed that PGE2-EP4 signaling mediates the 
induction of Treg by UV irradiation, and regulates UV-induced immunosuppression 
(Soontrapa et al.). Blockade of EP4 signaling suppresses the increase of Treg in dLNs and 
abolishes the immunosuppressive effect of UV. Blockade of EP4 signaling also diminishes 
the RANKL expression on KCs after UV irradiation (Soontrapa et al., 2011). It is known that 
RANKL expression on UV-irradiated KCs activates LCs, and the RANKL-activated LCs 
function to induce Treg in dLNs (Loser et al., 2006). These results indicate that PGE2-EP4 
signaling regulates RANKL expression on KCs and controls Treg induction from UV.  
Other than PGE2, it has been reported that PGD2 induces Treg differentiation through DP in 
a mouse asthma model (Hammad et al., 2007). Inhalation of a selective DP1 agonist 
suppressed the cardinal features of asthma by targeting the function of lung DCs. In mice 
treated with a DP1 agonist or receiving DP1 agonist-treated DCs, there was an increase in 
Tregs that suppressed inflammation in an IL-10-dependent way (Hammad et al., 2007). 
These effects of a DP1 agonist on DCs were mediated by cyclic AMP-dependent protein 
kinase A. Taken together, control of EP4 and/or DP1 signaling could represent a novel 
immunosuppressive approach. 
9. Prostanoids as inflammatory mediators 
In an established AD lesion, numerous inflammatory mediators such as cytokines (e.g., IL-4, 
IL-5, IL-13) and chemokines (e.g., CCL5, CCL11, CCL17) contribute to the development of 
AD (Guttman-Yassky et al.). 
As for the inflammatory mediators in AD lesions, the role of PGD2-CRTH2 signaling has 
been the most frequently investigated. In the skin, PGD2 is the major prostanoid produced 
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by activated mast cells. PGD2 has two types of receptors, DP and CRTH2. CRTH2 induces 
chemotaxis in Th2 cells, eosinophils and basophils with enhanced degranulation in vitro 
(Hirai et al., 2001; Yoshimura-Uchiyama et al., 2004). CRTH2 amplifies Th2 responses by 
preventing apoptosis of Th2 cells and enhancing their capacity to secrete cytokines (Nomiya 
et al., 2008; Xue et al., 2009). CRTH2 also amplifies eosinophil functions by mobilizing them 
from the bone marrow, preventing their apoptosis, and promoting their chemokinesis and 
degranulation (Gervais et al., 2001). CRTH2 mRNA expression is high in peripheral blood 
mononuclear cells of patients with AD (Hijnen et al., 2005), and circulating eosinophils and 
T cells in patients with AD have an increased surface expression of CRTH2 (Iwasaki et al., 
2002), suggesting the role of CRTH2 in AD. 
He et al. have recently reported that lack of CRTH2 signaling ameliorates the inflammation 
only in newly-challenged skin, while loss of this signaling in chronic challenged areas did 
not affect the inflammation (He et al., 2011). They used CRTH2 knockout mice in two types 
of AD models: one that was repeatedly sensitized with OVA for a total of seven weeks, 
which mimicked the chronic lesions of AD; and one that was challenged with OVA after the 
repeated sensitization of other skin areas for a total of seven weeks, which was supposed to 
mimic the acute lesions of AD. In the chronic lesions, the inflammatory cell infiltration and 
cytokine concentration was similar between wild-type and CRTH2 knockout mice, while in 
the acute lesions, such factors were significantly decreased in CRTH2 knockout mice 
compared with wild-type mice (He et al.). Consistently, the concentration of PGD2 increased 
significantly in the acute lesions, while the concentration of PGD2 in the chronic lesions was 
similar compared with that of non-affected skin. CRTH2 knockout mice also showed 
comparable levels of IgE production, indicating that CRTH2 signaling had little effect much 
on the antibody production process. Boehme et al. have previously reported that 
administration of a CRTH2 antagonist inhibited the development of chronic AD lesions in 
the same model (Boehme et al., 2009), but the CRTH2 antagonist-treated group also showed 
reduced IgE production, suggesting the possibility that administration of the CRTH2 
antagonist affected the extent of sensitization non-specifically and thus lead to the reduced 
inflammatory cell infiltration in the skin. Collectively, blockage of PGD2-CRTH2 signaling 
might inhibit allergic skin inflammation elicited in patients with AD by re-exposure to 
antigens to which they have been sensitized (Figure 3). 
In contrast, stimulation of EP3-signaling in KCs is reported to play an anti-inflammatory 
role in skin inflammation by inhibiting chemokine production from KCs (Honda et al., 
2009). Administration of an EP3 specific agonist suppressed a CHS response, and EP3 
knockout mice showed an enhanced CHS response, suggesting that PGE2-EP3 signaling 
works as a negative regulator of allergic cutaneous inflammation. An anti-inflammatory role 
of EP3 signaling is also reported in other allergic diseases such as mouse asthma and the 
allergic conjunctivitis model (Kunikata et al., 2005; Ueta et al., 2009). 
10. Prostanoids as itch mediators 
It is reported that some prostanoids can modulate pruritus, a significant hallmark of AD. In 
human studies, PGE2 is a weak pruritogen and prolongs experimentally-induced itch 
(Hagermark and Strandberg, 1977; Neisius et al., 2002), although injection of PGE2 alone 
does not elicit itch-associated response in animal experiments (Andoh and Kuraishi, 1998). 
TXA2 is also reported as a mediator of itch (Andoh et al., 2007). Injection of a TP agonist 
alone elicited itch-associated responses. TP was expressed in both KCs and nerve fibers in 
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skin (Andoh et al., 2007). TX synthase was also expressed in KCs. In some studies, the 
association of genetic polymorphisms in the TP gene with asthma and atopy has been 
reported (Shin et al., 2003). TXA2 may be involved in the pathogenesis of atopic disease not 
only as an airway constriction factor but also as an itch mediator. 
On the other hand, PGD2 is reported to play anti-pruritic roles in the mouse AD model (Arai 
et al., 2004). Administration of PGD2 and a DP1 agonist reduced scratching behaviors in an 
AD model using NC/Nga mice, while administration of a DP2 agonist did not reduce such 
behavior (Arai et al., 2004). Inhibition of histamine release from mast cells is proposed as a 
possible suppression mechanism of the DP signaling (Hashimoto et al., 2005). Blockade of 
TP signaling or stimulation of DP1 signaling may lead to a new target for the treatment of 
pruritic disease, including AD. 
 
 
Fig. 2. Regulation of DC migration and Th differentiation by prostanoids 
During the sensitization period, antigens induce pro-inflammatory cytokine secretion by 
KCs, which enhances cutaneous DC (LCs and dDCs) activation and migration to dLNs. In 
the LNs, cutaneous DCs activate naïve T cells that differentiate into mature memory T cells. 
During antigen exposure to the skin, KCs produce PGE2 and mast cells produce PGD2. 
Moreover, schistosomes produce PGD2 during a helminthic infection. The PGE2-EP4 pathway 
promotes, but PGD2-DP and PGI2-IP pathways inhibit cutaneous DC migration and 
maturation. TXA2 produced by activated cutaneous DCs seems to act on naïve T cells to 
disrupt DC-T cell interaction. The PGE2-EP1/EP2/EP4 pathways promote Th1 cell 
differentiation, and the PGE2-EP4 pathway also promotes Th17 cell expansion. 
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Fig. 3. Prostanoids as inflammatory/itch mediators 
Repeated antigen exposure to the skin stimulates KCs to secrete pro-inflammatory 
cytokines, chemokines and other mediators, which activate the endothelial activation of 
blood vessels. This activation attracts memory T cell infiltration into the skin. PGE2 dilates 
blood vessels possibly through EP2 and EP4. The PGD2-CRTH2 signaling promotes Th2 
cells/eosinophils/neutrophils infiltration in skin. The PGE2-EP3 signaling inhibits KC 
activation and plays an anti-inflammatory role in CHS. The TP signaling mediates itch 
signaling through afferent nerves, while stimulation of DP signaling inhibits itch-
associated responses. 
11. Summary and future direction 
NSAIDs, which block the production of all prostanoids, usually have limited effects on 
AD (Kabashima and Miyachi, 2004) and therefore have not been given so much attention 
as a potential therapeutic agent. However, the analysis using the receptor knockout mice 
and receptor specific drugs has revealed new unexpected roles of prostanoids in the 
immune systems. In addition, signaling from even the same receptor can produce the 
opposite effect depending on the context, such as the Th1 modulating effect generated 
through EP2/EP4 signaling (Yao et al., 2009). Therefore, it would be necessary to 
reconsider the role of prostanoids in the development of AD. It is also important to 
correlate these immunomodulatory actions of prostanoids found in mice to their actions 
in immune diseases of humans. Currently, CRTH2 antagonists are on their way to being 
used in clinical applications for AD or asthma (Ulven and Kostenis., 2010). Further 
analysis of the role of each prostanoid receptor has great potential in leading to a new 
therapeutic target for AD. 
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